Contact the Editorial Desk

Editorial correspondence

Correspondence on the research record is welcome: a citation quoted inaccurately, a newly published trial on CJC-1295, ipamorelin, or MOTS-c, a corrected effect size, or a study-design detail the logbook got wrong. A message that improves the accuracy of a specific claim on a specific page is the most useful thing that lands here, and each one is read carefully.

The most actionable notes specify the page in question, the exact claim being corrected, and the supporting source, ideally with a DOI or PubMed identifier. That format lets a proposed correction be verified against its source before anything on the site changes.

Editorial mailbox: editors@peptidecycles.com

What this desk cannot do

Peptide Cycles reads the literature; it is not a clinical service or a product vendor, so it cannot advise on or recommend human use of any peptide covered here, cannot suggest a dose or schedule for any individual, cannot judge whether a specific study's findings apply to a specific person's situation, and cannot help locate, source, or recommend a supplier for any compound. None of the three compounds covered here is approved for human use anywhere; anyone seeking clinical guidance should consult a licensed healthcare provider in their own jurisdiction. Replies to editorial correspondence are not guaranteed and may be delayed; the mailbox is watched intermittently.